These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Is heparin reversal with protamine after carotid endarterectomy dangerous? Dellagrammaticas D; Lewis SC; Gough MJ; Eur J Vasc Endovasc Surg; 2008 Jul; 36(1):41-4. PubMed ID: 18406179 [TBL] [Abstract][Full Text] [Related]
26. Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate. Blombäck M; He S; Bark N; Wallen HN; Elg M Br J Haematol; 2011 Mar; 152(6):758-65. PubMed ID: 21250974 [TBL] [Abstract][Full Text] [Related]
27. An oral vitamin K protocol to reverse over-anticoagulation in patients presenting with an International Normalised Ratio above 10.0. Denas G; Cucchini U; Iliceto S; Pengo V Thromb Haemost; 2009 Feb; 101(2):410-1. PubMed ID: 19190831 [No Abstract] [Full Text] [Related]
29. Intracranial hemorrhage: how to return from the Warfarin effect. Solari D; Cavallo LM World Neurosurg; 2014 Jan; 81(1):40-2. PubMed ID: 23380281 [No Abstract] [Full Text] [Related]
30. The direct thrombin inhibitor hirudin. Greinacher A; Warkentin TE Thromb Haemost; 2008 May; 99(5):819-29. PubMed ID: 18449411 [TBL] [Abstract][Full Text] [Related]
31. Recombinant activated factor VII as a temporary reversal agent for warfarin anticoagulation: a cautionary report on an off-label application. Kalainov DM; Valentino LA Am J Orthop (Belle Mead NJ); 2008 Nov; 37(11):572-4. PubMed ID: 19104685 [No Abstract] [Full Text] [Related]
33. The effect of suramin on laboratory tests of coagulation. Horne MK; Wilson OJ; Cooper M; Gralnick HR; Myers CE Thromb Haemost; 1992 Apr; 67(4):434-9. PubMed ID: 1631791 [TBL] [Abstract][Full Text] [Related]
34. Warfarin-reversal: results of a phase III study with pasteurised, nanofiltrated prothrombin complex concentrate. Pabinger-Fasching I Thromb Res; 2008; 122 Suppl 2():S19-22. PubMed ID: 18549908 [TBL] [Abstract][Full Text] [Related]
35. [Inhibition of plasmatic coagulation: what is new?]. Schwarz M; Bode C Hamostaseologie; 2006 May; 26(2):154-7. PubMed ID: 16676059 [TBL] [Abstract][Full Text] [Related]
36. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Levi M; Toh CH; Thachil J; Watson HG Br J Haematol; 2009 Apr; 145(1):24-33. PubMed ID: 19222477 [TBL] [Abstract][Full Text] [Related]
37. RNA aptamers as reversible antagonists of coagulation factor IXa. Rusconi CP; Scardino E; Layzer J; Pitoc GA; Ortel TL; Monroe D; Sullenger BA Nature; 2002 Sep; 419(6902):90-4. PubMed ID: 12214238 [TBL] [Abstract][Full Text] [Related]
38. Anticoagulation and reversal paradigms: is too much of a good thing bad? Levy JH; Tanaka KA Anesth Analg; 2009 Mar; 108(3):692-4. PubMed ID: 19224768 [No Abstract] [Full Text] [Related]
39. Vitamin K deficiency amplifies anticoagulation response to ximelagatran: possible implications for direct thrombin inhibitors and their clinical safety. Kamali F; Wood P; Ward A Ann Hematol; 2009 Feb; 88(2):141-9. PubMed ID: 18716776 [TBL] [Abstract][Full Text] [Related]